Fny Investment Advisers, LLC Inmune Bio, Inc. Transaction History

Fny Investment Advisers, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 12, 2024	BUY	$6.6 - $11.52 $660 - $1,152	100 New	100 $1,000
Q4 2022 Jan 10, 2023	SELL	$6.13 - $7.96 $919 - $1,194	-150 Reduced 60.0%	100 $0
Q2 2022 Jul 12, 2022	SELL	$5.48 - $8.97 $1,370 - $2,242	-250 Reduced 50.0%	250 $2,000
Q1 2022 Apr 25, 2022	SELL	$6.42 - $11.39 $3,852 - $6,834	-600 Reduced 54.55%	500 $4,000
Q4 2021 Jan 10, 2022	BUY	$9.97 - $20.38 $2,991 - $6,114	300 Added 37.5%	1,100 $11,000
Q3 2021 Oct 13, 2021	BUY	$14.13 - $27.85 $7,065 - $13,925	500 Added 166.67%	800 $15,000
Q2 2021 Jul 14, 2021	SELL	$9.29 - $19.33 $54,810 - $114,046	-5,900 Reduced 95.16%	300 $5,000
Q1 2021 Apr 12, 2021	BUY	$11.61 - $26.85 $20,898 - $48,330	1,800 Added 40.91%	6,200 $73,000
Q4 2020 Jan 19, 2021	BUY	$7.51 - $17.22 $6,008 - $13,776	800 Added 22.22%	4,400 $75,000
Q3 2020 Oct 09, 2020	BUY	$4.92 - $15.75 $12,792 - $40,950	2,600 Added 260.0%	3,600 $37,000
Q2 2020 Jul 10, 2020	BUY	$3.1 - $6.09 $3,100 - $6,090	1,000 New	1,000 $5,000
Q2 2019 Jul 24, 2019	SELL	$7.45 - $11.0 $1,490 - $2,200	-200 Closed	0 $0
Q1 2019 Apr 17, 2019	BUY	$7.08 - $8.2 $1,416 - $1,639	200 New	200 $1,000

5.88M

243K

46.4K

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $89M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

Get notified when there are updates to the investment portfolio of Fny Investment Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Fny Investment Advisers, LLC with notifications on news.